Clinical Trial: ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies

Study Status: Active, not recruiting
Recruit Status: Active, not recruiting
Study Type: Interventional

Official Title: A Phase 1b/2 Proof-of-Concept Study of the Combination of ACP-196 (Acalabrutinib) and Pembrolizumab in Subjects With Hematologic Malignancies

Brief Summary: This study is evaluating the safety, pharmacodynamics (PD), and efficacy of acalabrutinib and pembrolizumab in hematologic malignancies.

Detailed Summary:
Sponsor: Acerta Pharma BV

Current Primary Outcome: Number of Participants With Treatment Emergent Adverse Events (AEs) [ Time Frame: 104 weeks ]

Original Primary Outcome: Number of Participants With Treatment Emergent Adverse Events (AEs) [ Time Frame: 52 weeks ]

Current Secondary Outcome:

Original Secondary Outcome:

Information By: Acerta Pharma BV

Dates:
Date Received: February 7, 2015
Date Started: February 2015
Date Completion: April 2021
Last Updated: May 19, 2017
Last Verified: May 2017